UNSPSC 51112612: Semustine

This classification denotes a nitrosourea compound, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6YY7T1T567. European Medicines Agency schedules Semustine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10482MIG. Semustine generally arises in the molecular formula C10H18CLN3O2.

UNSPSC 51112612 Semustine is a Commodity code representing pharmaceutical products—specifically semustine, a chemotherapy agent—that state and local health and human services agencies procure through pharmacy benefit programs and direct contracting mechanisms. State and local governments buying under this code are primarily state health departments and Medicaid agencies that source controlled pharmaceutical inventory for state employee health plans, Medicaid beneficiaries, and correctional or public health facilities. The work involves vendor qualification for direct-to-manufacturer prescription fulfillment, negotiation of net pricing models outside traditional pharmacy benefit manager and group purchasing organization channels, and implementation of value-based or outcomes-based pharmaceutical agreements that improve cost management and prescription fulfillment efficiency.

Texas Health and Human Services Commission posted Request for Information RFI No. HHS0017013 on April 3, 2026, to gather vendor capabilities and market intelligence for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program. The RFI seeks responses from vendors with demonstrated experience in direct contracting for self-insured employers and health plans in both private and government sectors within the prior two years, flexibility to negotiate contracts using negotiated net pricing models without rebates, and capacity to implement value-based or outcomes-based agreements. The state intends to use vendor responses from this preliminary information-gathering phase to inform future procurement strategy and develop detailed specifications for subsequent formal solicitations; no award value, budget range, or specific timeline for formal RFP issuance is identified in current materials.